Market Place
Sourcing Support
Discover our 2023 Sustainability Report
07 Oct 2024 //
PRESS RELEASE
Ferrer Advances Research Into PSP First Participant Ph II Trial
08 Aug 2024 //
PRESS RELEASE
Ferrer obtains the distribution rights of a potential treatment for IPF & PPF
24 May 2024 //
PRESS RELEASE
People living with pulmonary hypertension call for better psychological support
21 Apr 2024 //
PRESS RELEASE
Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
25 Mar 2024 //
PRESS RELEASE
CDP rates us among the leading companies in the fight against climate change
06 Feb 2024 //
PRESS RELEASE
We are EcoVadis Platinum
31 Jan 2024 //
PRESS RELEASE
Ferrer reports top-line results from Phase III ADORE study in ALS
10 Jan 2024 //
PRESS RELEASE
More than 350 Latin American doctors participate in the second Ferrer Summit in the region
23 Oct 2023 //
PRESS RELEASE
More than 1,200 Ferrer volunteers join in a global commitment to social justice during our Days for Good
09 Oct 2023 //
PRESS RELEASE
We allocate more than 40% of our profits to social and environmental projects for the third consecutive year
11 Jul 2023 //
PRESS RELEASE
We extend our clinical trial in amyotrophic lateral sclerosis
21 Jun 2023 //
PRESS RELEASE
Ferrer4Future launches an open innovation challenge to promote digital solutions for ALS
21 Jun 2023 //
PRESS RELEASE
We’ve been awarded EcoVadis GOLD Rating!
30 Mar 2023 //
PRESS RELEASE
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)
22 Feb 2023 //
PRESS RELEASE
The Bellvitge University Hospital and Ferrer collaborate to promote innovation in the field of health
21 Feb 2023 //
PRESS RELEASE
We achieve Great Place To Work certification in 5 countries
29 Nov 2022 //
PRESS RELEASE
The Ferrer-Salat Music Foundation celebrates 40 years contributing to musical excellence and social integration
25 Nov 2022 //
PRESS RELEASE
More than 500 people from Ferrer participate in +ve impact in 9 countries
07 Oct 2022 //
PRESS RELEASE
The polypill reduces cardiovascular mortality by 33% in patients treated MI
25 Aug 2022 //
PRESS RELEASE
We invested more than 60% of our net profits in social and environmental causes
28 Jul 2022 //
PRESS RELEASE
We bring ALSton the dragon to life to raise awareness of ALS
21 Jun 2022 //
PRESS RELEASE
We consolidate our commitment to flexible working
15 Jun 2022 //
PRESS RELEASE
Ferrer participates in B Lab Spain`s B Good Day
27 May 2022 //
PRESS RELEASE
Improving clinical research for people with (CVS), the new challenge
11 May 2022 //
PRESS RELEASE
Ferrer brings the first PHantasticals to life to raise awareness of PH
05 May 2022 //
PRESS RELEASE
Ferrer, strategic partner of Barcelona+B, the initiative to promote a prosperous
26 Apr 2022 //
PRESS RELEASE
More than 400 employees from Ferrer take part in a social initiative in Spain
08 Apr 2022 //
PRESS RELEASE
Improving clinical research for people with Cyclic Vomiting Syndrome (CVS)
11 Mar 2022 //
PRESS RELEASE
Ferrer, the first pharmaceutical company committed to recovering waste medicines
09 Mar 2022 //
PRESS RELEASE
Ferrer brings the first PHantasticals to lifeawareness of Pulmonary Hypertension
05 Mar 2022 //
PRESS RELEASE
Details of Clinical Trial ADORE for Amyotrophic Lateral Sclerosis (ALS)
24 Feb 2022 //
PRESS RELEASE
Ferrer announces distribution agreement United Therapeutics for treprostinil
23 Feb 2022 //
PRESS RELEASE
Ferrer becomes a B Corp for its positive impact in society
25 Jan 2022 //
PRESS RELEASE
Details of the phase III clinical trial, ADORE, in amyotrophic lateral sclerosis (ALS)
13 Dec 2021 //
PRESS RELEASE
Ferrer joins Barcelona + B, project to bring the business community closer SDGs
29 Nov 2021 //
PRESS RELEASE
First patient enrolled in Ferrer`s FNP122 ADORE Phase III clinical trial
08 Nov 2021 //
PRESS RELEASE
Ferrer signs license agreement to develop an oral formulation treatment
20 Oct 2021 //
PRESS RELEASE
We launched the third edition of the Ferrer 4 Future program
07 Jun 2021 //
PRESS RELEASE
We open new headquarters in Barcelona
12 May 2021 //
PRESS RELEASE
Ferrer is certified as an excellent place to work, putting people at the center of its cultural transformation
22 Apr 2021 //
PRESS RELEASE
Ferrer launches one of the most effective oral lipid-lowering agents on the market
25 Feb 2021 //
PRESS RELEASE
Ferrer takes a further step in its strategy and diverts from HealthTech BioActives
13 Dec 2020 //
PRESS RELEASE
We maintain a firm commitment to sustainability and the circular economy
18 Jun 2020 //
PRESS RELEASE
Ferrer cooperates with the Hospital del Mar in Barcelona in a project on COVID-19
18 Jun 2020 //
PRESS RELEASE
We are strongly committed to sustainability and we are adopting measures to promote the circular economy
18 Jun 2020 //
PRESS RELEASE
Ferrer launches a new, disruptive, more accessible corporate website focused on transparency
18 Jun 2020 //
PRESS RELEASE
Ferrer cooperates with the Hospital del Mar de Barcelona in a project on COVID-19
18 Jun 2020 //
PRESS RELEASE
Add Interquim Project: PCS7 updating project in a regulated Pharma environment
02 Mar 2020 //
PRESS RELEASE
Scientists from the University of Pardubice have optimized the production of human and veterinary medicines
26 Feb 2020 //
PRESS RELEASE
Ferrer unloads another business to focus on branded drugs
17 Dec 2019 //
FIERCE PHARMA
Ferrer workers exchange office tools for picks and shovels
28 Aug 2019 //
PRESS RELEASE
Castilla y León, meeting point for knowledge in cardiology
19 Jun 2019 //
PRESS RELEASE
